Viracta Therapeutics, Inc. (VIRX)
USD 0.02
(14.44%)
USD 0.02
(14.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -50.69 Million USD | -0.21% |
| 2022 | -50.58 Million USD | -180.94% |
| 2021 | 62.5 Million USD | 432.19% |
| 2020 | -18.81 Million USD | 19.21% |
| 2019 | -23.28 Million USD | 9.42% |
| 2018 | -25.71 Million USD | 25.3% |
| 2017 | -34.41 Million USD | 5.6% |
| 2016 | -36.46 Million USD | 7.23% |
| 2015 | -39.3 Million USD | 4.8% |
| 2014 | -41.28 Million USD | -30.31% |
| 2013 | -31.68 Million USD | 24.74% |
| 2012 | -42.09 Million USD | -112.17% |
| 2011 | -19.84 Million USD | 19.3% |
| 2010 | -24.58 Million USD | 38.87% |
| 2009 | -40.22 Million USD | -8.67% |
| 2008 | -37.01 Million USD | 3.99% |
| 2007 | -38.55 Million USD | -25.33% |
| 2006 | -30.75 Million USD | -14.67% |
| 2005 | -26.82 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -13.87 Million USD | -2.33% |
| 2024 Q2 | -9.58 Million USD | 30.9% |
| 2023 Q3 | -12.47 Million USD | -0.2% |
| 2023 Q1 | -12.2 Million USD | -5.47% |
| 2023 Q2 | -12.45 Million USD | -1.99% |
| 2023 FY | -50.69 Million USD | -0.21% |
| 2023 Q4 | -13.56 Million USD | -8.7% |
| 2022 Q2 | -10.5 Million USD | -0.7% |
| 2022 FY | -50.58 Million USD | -180.94% |
| 2022 Q1 | -10.43 Million USD | 7.83% |
| 2022 Q4 | -11.57 Million USD | 35.98% |
| 2022 Q3 | -18.07 Million USD | -72.09% |
| 2021 Q2 | -9.31 Million USD | 88.18% |
| 2021 Q1 | -78.84 Million USD | -1187.01% |
| 2021 Q4 | -11.31 Million USD | 23.52% |
| 2021 Q3 | -14.79 Million USD | -58.84% |
| 2021 FY | 62.5 Million USD | 432.19% |
| 2020 Q4 | -6.12 Million USD | -53.46% |
| 2020 Q1 | -4.45 Million USD | 14.55% |
| 2020 FY | -18.81 Million USD | 19.21% |
| 2020 Q2 | -4.24 Million USD | 4.87% |
| 2020 Q3 | -3.99 Million USD | 5.85% |
| 2019 Q2 | -6.13 Million USD | -9.48% |
| 2019 Q3 | -5.87 Million USD | 4.23% |
| 2019 Q4 | -5.21 Million USD | 11.16% |
| 2019 FY | -23.28 Million USD | 9.42% |
| 2019 Q1 | -5.59 Million USD | 1.81% |
| 2018 Q3 | -6.21 Million USD | 5.17% |
| 2018 FY | -25.71 Million USD | 25.3% |
| 2018 Q2 | -6.55 Million USD | 6.28% |
| 2018 Q1 | -6.99 Million USD | -10.23% |
| 2018 Q4 | -5.7 Million USD | 8.24% |
| 2017 Q4 | -6.34 Million USD | 35.74% |
| 2017 Q3 | -9.87 Million USD | -16.16% |
| 2017 FY | -34.41 Million USD | 5.6% |
| 2017 Q2 | -8.49 Million USD | 9.11% |
| 2017 Q1 | -9.35 Million USD | -15.96% |
| 2016 Q4 | -8.06 Million USD | 4.93% |
| 2016 Q3 | -8.48 Million USD | 14.93% |
| 2016 FY | -36.46 Million USD | 7.23% |
| 2016 Q2 | -9.97 Million USD | -1.86% |
| 2016 Q1 | -9.78 Million USD | 13.72% |
| 2015 FY | -39.3 Million USD | 4.8% |
| 2015 Q3 | -6.78 Million USD | 22.12% |
| 2015 Q4 | -11.34 Million USD | -67.12% |
| 2015 Q2 | -8.71 Million USD | 1.95% |
| 2015 Q1 | -8.88 Million USD | -778.36% |
| 2014 Q2 | -11.31 Million USD | 19.36% |
| 2014 FY | -41.28 Million USD | -30.31% |
| 2014 Q1 | -14.02 Million USD | -114.01% |
| 2014 Q4 | -1.01 Million USD | 93.22% |
| 2014 Q3 | -14.93 Million USD | -32.03% |
| 2013 Q4 | -6.55 Million USD | 5.18% |
| 2013 Q3 | -6.91 Million USD | 6.87% |
| 2013 FY | -31.68 Million USD | 24.74% |
| 2013 Q2 | -7.42 Million USD | 31.23% |
| 2013 Q1 | -10.79 Million USD | -235.92% |
| 2012 Q3 | -17.01 Million USD | -105.87% |
| 2012 FY | -42.09 Million USD | -112.17% |
| 2012 Q4 | -3.21 Million USD | 81.11% |
| 2012 Q1 | -13.6 Million USD | -55.71% |
| 2012 Q2 | -8.26 Million USD | 39.28% |
| 2011 Q3 | -5.01 Million USD | 39.05% |
| 2011 Q1 | 1.84 Million USD | 118.27% |
| 2011 Q2 | -8.22 Million USD | -547.12% |
| 2011 FY | -19.84 Million USD | 19.3% |
| 2011 Q4 | -8.74 Million USD | -74.31% |
| 2010 Q2 | -4.78 Million USD | -2.93% |
| 2010 FY | -24.58 Million USD | 38.87% |
| 2010 Q4 | -10.07 Million USD | -98.11% |
| 2010 Q3 | -5.08 Million USD | -6.27% |
| 2010 Q1 | -4.64 Million USD | -15.19% |
| 2009 FY | -40.22 Million USD | -8.67% |
| 2009 Q3 | -4.94 Million USD | 78.37% |
| 2009 Q2 | -22.87 Million USD | -173.57% |
| 2009 Q1 | -8.36 Million USD | -20.73% |
| 2009 Q4 | -4.03 Million USD | 18.47% |
| 2008 Q1 | -9.62 Million USD | -9.65% |
| 2008 Q3 | -7.06 Million USD | 47.93% |
| 2008 Q4 | -6.92 Million USD | 1.95% |
| 2008 Q2 | -13.56 Million USD | -40.97% |
| 2008 FY | -37.01 Million USD | 3.99% |
| 2007 Q3 | -10.84 Million USD | -10.96% |
| 2007 Q2 | -9.77 Million USD | -4.3% |
| 2007 Q1 | -9.36 Million USD | -3.75% |
| 2007 Q4 | -8.77 Million USD | 19.04% |
| 2007 FY | -38.55 Million USD | -25.33% |
| 2006 Q2 | -4.49 Million USD | 49.92% |
| 2006 Q4 | -9.03 Million USD | -3.39% |
| 2006 FY | -30.75 Million USD | -14.67% |
| 2006 Q1 | -8.97 Million USD | -68.92% |
| 2006 Q3 | -8.73 Million USD | -94.26% |
| 2005 Q3 | -5.59 Billion USD | 0.0% |
| 2005 FY | -26.82 Million USD | 0.0% |
| 2005 Q4 | -5.31 Million USD | 99.9% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -10189.986% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -432.601% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -69.016% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 24.5% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -219.971% |
| Better Therapeutics, Inc. | -38.26 Million USD | -32.489% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -20.485% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -323.5% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -49.784% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -47.282% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 53.264% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -2416.653% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -49.088% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -7.97% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -3607.293% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -154.237% |
| Molecular Templates, Inc. | -10.46 Million USD | -384.359% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -260.781% |
| NexImmune, Inc. | -29.19 Million USD | -73.651% |
| Orgenesis Inc. | -53.63 Million USD | 5.487% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 1.172% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -64876.864% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -213.981% |
| Scopus BioPharma Inc. | -11.71 Million USD | -332.723% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 89.948% |
| Statera Biopharma, Inc. | -98.34 Million USD | 48.453% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -634.894% |
| Trevena, Inc. | -35.28 Million USD | -43.655% |
| Vaxxinity, Inc. | -58.28 Million USD | 13.026% |
| Vaccinex, Inc. | -22.88 Million USD | -121.512% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -4741.84% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -597.961% |